enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...

3. Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field

   www.aol.com/news/eli-lilly-boehringer-share...

   In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...

4. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

5. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment

6. Lilly, Boehringer say Jardiance slows kidney disease ... - AOL

   www.aol.com/news/lilly-boehringer-jardiance...

   In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

8. Are berberine supplements actually ‘nature’s Ozempic’? Here’s ...

   www.aol.com/berberine-supplements-actually...

   Berberine has potential benefits for heart health, such as lowering triglycerides (fat in the blood), total and LDL cholesterol, and systolic blood pressure, says Dr. Lona Sandon, PhD, RDN, LD, a ...

9. Empagliflozin/linagliptin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin/linagliptin

   The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).